← Back to Search

Dopamine Precursor

Carbidopa-levodopa 2 tablets daily for Age-Related Macular Degeneration

Phase 2
Waitlist Available
Led By Robert W Snyder, MD, PhD
Research Sponsored by Snyder, Robert W., M.D., Ph.D., P.C.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change over 12 months
Awards & highlights

Study Summary

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to "wet" (neovascular) AMD. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Dry AMD and Geographic Atrophy, and measure the effects on visual acuity, area of geographic atrophy and other retinal abnormalities due to "dry" AMD.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change over 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change over 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area of Geographic Atrophy
Secondary outcome measures
Best Corrected Visual Acuity by ETDRS
Central retinal thickness
Development of neovascular macular degeneration

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: carbidopa-levodopa 6 tablets dailyExperimental Treatment1 Intervention
carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
Group II: Carbidopa-levodopa 2 tablets dailyExperimental Treatment1 Intervention
carbidopa-levodopa 25-100 mg 2 tablets daily hs
Group III: PlaceboPlacebo Group1 Intervention
Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carbidopa
FDA approved

Find a Location

Who is running the clinical trial?

Snyder, Robert W., M.D., Ph.D., P.C.Lead Sponsor
4 Previous Clinical Trials
88 Total Patients Enrolled
Robert W Snyder, MD, PhDPrincipal InvestigatorRobert Snyder, MD, PhD, PC
3 Previous Clinical Trials
56 Total Patients Enrolled
Timothy C Fagan, MDStudy DirectorRobert Snyder, MD, PhD, PC
3 Previous Clinical Trials
56 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2025